Clinical Trial Update: A Study of TNM001 in Chinese Healthy Preterm and Term Infants [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of TNM001 in healthy Chinese preterm and term infants has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• TNM001

Snippet

Sponsor: Zhuhai Trinomab Pharmaceutical Co., Ltd. | Conditions: Respiratory Syncytial Virus Infections | Phase 1, Phase 2 | Status: COMPLETED